Articles tagged "Hepatocellular carcinoma"

2022 American Transplant Congress
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Multicenter Analysis
M. L. Holzner¹, V. Mazzaferro², M. Droz dit Busset², L. Aldrighetti³, F. Ratti³, K. Hasegawa⁴, J. Arita⁴, G. Sapisochin⁵, P. Abreu⁵, W. Schoening⁶, N. Nevermann⁶, M. Schmelzle⁶, J. Pratschke⁶, S. Florman¹, K. Halazun⁷, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Mount Sinai, New York, NY, ²University of Milan, Milan, Italy, ³San Raffaele Hospital, Milan, Italy, ⁴University of Tokyo, Tokyo, Japan, ⁵University of Toronto, Toronto, ON, Canada, ⁶Charite University, Berlin, Germany, ⁷Weill Cornell Medical Center, New York, NY
*Purpose: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high and optimal therapy for recurrent ICC is challenging. Herein we assess the outcomes…
2022 American Transplant Congress
An International Multi-Institutional Comparison of Liver Transplantation for Hepatocellular Carcinoma: United States, United Kingdom, and Canada
T. Ivanics¹, D. Wallace², M. P. Claasen³, M. Patel⁴, W. Jassem⁵, K. Menon⁵, A. Suddle⁵, N. Heaton⁵, N. Mehta⁶, J. van der Meulen², G. Sapisochin³
¹University of Toronto - University Health Network, Toronto, ON, Canada, ²Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ³Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ⁴Division of Surgical Transplantation, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Institute of Liver Studies, King's College Hospital, London, United Kingdom, ⁶UCSF, San Francisco, CA
*Purpose: Hepatocellular carcinoma (HCC) has become a leading indication for liver transplantation (LT) globally. Given the scarcity of organs, the general consensus has been that…
2022 American Transplant Congress
Individual and Community-Level Social Determinants of Health in Liver Transplant
M. Yilma¹, R. Cogan², N. Mehta³, J. Neuhaus², J. Voelkel⁴, C. Light⁵, I. Allen², R. Hirose²
¹General Surgery, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴Kaiser Permanente Northern California, San Francisco, CA, ⁵UCSF Medical Center, San Francisco, CA
*Purpose: To investigate the individual and census-level social determinants of health on liver transplant listing.*Methods: Retrospective review of patients referred to the University of California…
2022 American Transplant Congress
Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: An Analysis of the European Liver Transplant Registry
M. P. Claasen¹, T. Ivanics², J. N. IJzermans¹, G. Sapisochin², W. Polak¹
¹HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands, ²Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: Little is known about combined hepatocellular-cholangiocarcinoma (cHCC-CCA) demographics and their long-term outcomes after liver transplantation (LT). By analysing data from the European Liver Transplant…
2022 American Transplant Congress
Ex Vivo Liver Resection and Autotransplantation – Should It Be Used More Frequently?
J. Weiner¹, A. Griesemer¹, A. Hemming², D. Levi³, T. Beduschi⁴, R. Matsumoto¹, A. Mathur¹, J. Emond¹, T. Kato¹
¹Columbia University Irving Medical Center, New York, NY, ²University of Iowa, Iowa City, IA, ³Atrium Health, Charlotte, NC, ⁴University of Florida, Gainesville, FL
*Purpose: Ex vivo liver resection expands the limits of resectability for advanced liver tumors but remains underutilized due to concerns about technical complexity and vascular…
2022 American Transplant Congress
Outcomes of ABO-Incompatible Adult Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria
B. Lee, J. Cho, H. Lee
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
*Purpose: Given the organ scarcity, ABO incompatible (ABOi) living donor liver transplantation (LDLT) emerged as a treatment option for hepatocellular carcinoma (HCC) and underlying liver…
2022 American Transplant Congress
Tumor Suppressor Role of the Caveolar α1-na/k-atpase Signalosome in Nash Related Hepatocellular Carcinoma (HCC)
U. Udoh¹, M. Banerjee¹, J. D. Sanabria¹, P. K. Rajan¹, M. Schade², J. A. Sanabria³, S. Pierre³, J. R. Sanabria⁴
¹Surgery, Marshall Institute for Interdisciplinary Research, Barboursville, WV, ²Medicine, Joan C. Edwards School of Medicine, Marshall University, Barboursville, WV, ³Surgery, Joan C. Edwards School of Medicine, Marshall University, Barboursville, WV, ⁴Surgery, Joan C. Edwards School of Medicine, Marshall University and Case Western Reserve University, Barboursville, WV
*Purpose: HCC is the second and fastest-growing cause of cancer- related mortality worldwide, with an estimate of 0.84million cases/year. In the Western countries, due to…
2022 American Transplant Congress
Impacts Of Donor Gender On Recurrent Hepatocellular Carcinoma In Liver Transplant Donated After Brain Death
T. Nakamura¹, K. Sasaki², T. Yamamoto¹, S. Kimura¹, L. Dageforde¹, H. Yeh¹, N. Elias¹, T. Kawai¹, J. F. Markmann¹
¹Division of Transplant Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Abdominal Transplantation, Stanford University, Stanford, CA
*Purpose: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. It is well known that HCC is predominant in males and prognosis…
2022 American Transplant Congress
Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality
S. Weeks, T. Ishaque, A. Massie, D. Segev, E. King
Johns Hopkins, Baltimore, MD
*Purpose: Liver transplant candidates with hepatocellular carcinoma (HCC) risk tumor progression that may disqualify them from transplant eligibility while awaiting HCC exception points on the…
2022 American Transplant Congress
The Feasibility of Changing HCC MELD Exception Criteria to an Exclusive DCD-Only Option: A Strategy to Increase DCD Utilization
G. J. McKenna, P. Schultz, M. Finotti, M. Rosenzweig, A. Gupta, S. H. Lee, A. Wall, E. Martinez, J. Bayer, H. Fernandez, N. Onaca, R. Ruiz, G. Testa
Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
*Purpose: Outcomes of DCD liver transplantation is comparable to DBD but routine utilization of DCD liver grafts is surprisingly uneven in the US. A more…